Gliosarcoma Separates from Conventional Glioblastoma by a TP53/RB1-High, EGFR-Low Alteration Pattern Rather Than by Global Genomic Burden
Rare glioblastoma variants are usually treated as ordinary glioblastoma because prospective variant-specific cohorts are scarce. That default is practical, but it risks erasing biology that should matter for diagnosis and trial design. We reanalyzed public cBioPortal clinical sequencing data from the MSK 2019 glioma cohort, comparing 18 gliosarcoma samples with 539 conventional glioblastoma samples, and used TCGA PanCancer Atlas and CPTAC 2021 glioblastoma cohorts as external GBM baselines. Gene-level Fisher exact tests, burden comparisons, and a primary treatment-naive sensitivity analysis were used to distinguish recurrent alteration patterns from treatment and sampling artifacts. In the full MSK comparison, gliosarcoma was enriched for TP53 alteration (14/18 versus 183/539, q = 0.0067) and RB1 alteration (8/18 versus 78/539, q = 0.0258), and depleted for EGFR alteration (1/18 versus 219/539, q = 0.0258). PTEN alteration was directionally higher but did not survive FDR correction. In primary treatment-naive tumors, the same directions persisted, but gliosarcoma sample size fell to 11 and false-discovery-adjusted significance was lost. Tumor mutation burden and fraction genome altered were not significantly different. These data support gliosarcoma as a pathway-distinct glioblastoma variant, not merely a globally more unstable GBM subset. The finding is small-cohort evidence, but it is strong enough to argue that gliosarcoma should be stratified rather than silently pooled in molecular studies and clinical trials.
Reviews
This study uses a reasonable and transparent reanalysis of public MSK-IMPACT/cBioPortal data to ask a narrow question: whether gliosarcoma differs from conventional glioblastoma by specific pathway alterations versus overall genomic “burden.” The main positive is that the signal it highlights (TP53 and RB1 enriched; EGFR depleted) is directionally large and biologically coherent with known GBM archetypes, and the authors attempt to address a key confounder (treatment/recurrence) via a treatment-naive sensitivity analysis. The negative result on global measures (TMB, fraction genome altered) is also appropriate given the stated hypothesis and helps avoid overclaiming generalized instability. The major limitation is statistical fragility driven by the very small gliosarcoma sample (n=18; n=11 treatment-naive) and the heavy dependence on one clinical sequencing panel cohort with potential selection biases (referral patterns, sampling of recurrent disease, histopathologic misclassification, and panel-specific detection differences for CNAs such as EGFR amplification). Loss of FDR significance in the treatment-naive subset weakens the causal interpretation that the pattern is intrinsic rather than treatment-associated, and the use of external cohorts only as “baselines” (rather than matched comparisons with harmonized variant calling and alteration definitions) limits how strongly one can generalize. Overall, the conclusion that gliosarcoma shows a TP53/RB1-high, EGFR-low pattern is supported as an association in this dataset; the stronger recommendation about trial stratification is plausible but should be framed as provisional pending larger, pathology-confirmed cohorts and harmonized multi-cohort validation.